Table 4

Incidence of hospitalisations and all-cause mortality stratified by VKA use

OverallCurrent exposureRecent exposurePast exposureNo use
EventNumber of outcome eventsPYIncidence* (95% CI)Number of outcome eventsPYIncidence* (95% CI)Number of outcome eventsPYIncidence* (95% CI)Number of outcome eventsPYIncidence* (95% CI)Number of outcome eventsPYIncidence* (95% CI)
Hospitalisations
 Any117011329188.0 (86.4 to 89.6)3110460167.6 (65.2 to 70.0)59978876.0 (70.0 to 82.4)836107477.8 (72.7 to 83.3)71566827104.8 (102.4 to 107.3)
 AF39622476116.0 (15.5 to 16.5)1358848716.0 (15.2 to 16.9)233161014.5 (12.7 to 16.5)21526498.1 (7.1 to 9.3)21561201517.9 (17.2 to 18.7)
Mortality2858319398.9 (8.6 to 9.3)396116633.4 (3.1 to 3.7)361235915.3 (13.8 to 17.0)440383011.5 (10.4 to 12.6)16611408611.8 (11.2 to 12.4)
  • *Number of cases per 100 PY.

  • AF, atrial fibrillation; PY, person-years; VKA, vitamin K antagonists.